文献速递银屑病与炎症性皮肤病

IL-17A基因编码区及非翻译区遗传变异无法解释司库奇尤单抗与依奇珠单抗的疗效反应:四欧洲队列多中心研究

Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2019-08-05

该多中心欧洲队列研究纳入134例接受司库奇尤单抗或依奇珠单抗治疗的斑块状银屑病患者,对IL-17A基因编码区及非翻译区进行Sanger测序,并分析5个非编码区遗传变异与12周和24周疗效的关联。结果显示,12周时62%患者达PASI75、39%达PASI90;24周时分别为72%和62%。5个遗传变异与ΔPASI、PASI75或PASI90均无关联,提示IL-17A基因编码区及非翻译区变异不能解释上述药物的疗效反应。

要点

  • IL-17A基因编码区及非翻译区变异与司库奇尤单抗/依奇珠单抗12周和24周疗效无关联。
  • 12周时62%患者达PASI75、39%达PASI90;24周时分别为72%和62%。
  • 抗IL-17A药物的药物遗传学仍需进一步探索。

核心结论

  • 司库奇尤单抗和依奇珠单抗的疗效反应无法由IL-17A基因编码区及非翻译区的遗传变异解释。

研究设计与样本

  • 多中心欧洲队列研究,纳入134例接受司库奇尤单抗或依奇珠单抗治疗的斑块状银屑病患者。
  • 对IL-17A基因编码区及非翻译区进行Sanger测序,采用线性回归模型分析遗传变异与疗效的关联。

主要发现

  • 12周时62%患者达PASI75、39%达PASI90;24周时PASI75和PASI90应答率分别为72%和62%。
  • 5个非编码区遗传变异(rs2275913、rs8193037、rs3819025、rs7747909、rs3748067)与12周和24周的ΔPASI、PASI75或PASI90均无关联。

关键数值与推荐

  • 主要结局为12周ΔPASI,次要结局为24周ΔPASI。
  • 关联分析校正基线PASI(固定协变量)、生物制剂初治状态和体重指数。
  • 基因分型仅发现非翻译区和内含子DNA变异,未发现编码区变异。

临床怎么用

  • 目前不建议依据IL-17A基因编码区及非翻译区变异来预测司库奇尤单抗或依奇珠单抗的疗效。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Genetic predictors for treatment response could optimize allocation of biological treatment in patients with psoriasis. There is minimal knowledge about pharmacogenetics of anti-IL-17 agents. OBJECTIVES: To assess whether genetic variants in the protein-coding region or untranslated regions of the IL-17A gene are associated with response to IL-17A inhibitors in patients with psoriasis. METHODS: This was a multicenter European cohort study investigating pharmacogenetics of IL-17A inhibitors in patients with psoriasis. Patients with plaque psoriasis treated with secukinumab or ixekizumab in daily practice were included. For all participants, the protein-coding region and untranslated regions of the IL-17A gene were analysed using Sanger sequencing. Identified genetic variants were tested for association with response to secukinumab/ixekizumab, measured as ∆PASI, after 12 weeks (primary outcome) and after 24 weeks (secondary outcome). Association was tested using a linear regression model with correction for baseline PASI as a fixed covariate and for biological naivety and body mass index as additional covariates. RESULTS: In total, 134 patients treated with secukinumab or ixekizumab were included. Genotyping of the cohort identified genetic variants present in untranslated regions and intronic DNA, but not in the protein-coding region of the IL-17A gene. Five genetic variants in non-coding DNA with a known or suspected functional effect on IL-17A expression were selected for association analyses: rs2275913, rs8193037, rs3819025, rs7747909 and rs3748067. After 12 weeks, 62% of patients achieved PASI75 and 39% achieved PASI90. At week 24, PASI75 and PASI90 response rates were 72% and 62%, respectively. No associations were found between the five genetic variants and ∆PASI, PASI75 or PASI90 after 12 and 24 weeks of anti-IL-17A treatment. CONCLUSIONS: Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene. Pharmacogenetics of IL-17A inhibitors in the treatment of psoriasis requires further exploration.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. van Vugt LJ, van den Reek JMPA, Meulewaeter E, et al. Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts. J Eur Acad Dermatol Venereol. 2019. PMID: 31287604. doi:10.1111/jdv.15787

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。